Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
about
Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patientsMathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.Herpes simplex virus-2 transmission probability estimates based on quantity of viral sheddingDoes maternal HSV-2 coinfection increase mother-to-child transmission of HIV? A systematic review.Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract.Current status and prospects for development of an HSV vaccineAntiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosinIn vivo disruption of latent HSV by designer endonuclease therapyPersistence of mucosal T-cell responses to herpes simplex virus type 2 in the female genital tractImmunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigsEnhancement of herpes simplex virus (HSV) infection by seminal plasma and semen amyloids implicates a new target for the prevention of HSV infection.Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in femalesOral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial.Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract SheddingSynthetic α-Hydroxytropolones Inhibit Replication of Wild-Type and Acyclovir-Resistant Herpes Simplex Viruses.An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.Safety, formulation, and in vitro antiviral activity of the antimicrobial peptide subtilosin against herpes simplex virus type 1.Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action.In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 ReactivationTheaflavin-3,3'-digallate and lactic acid combinations reduce herpes simplex virus infectivity.Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy.Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.Design and implementation of a randomized crossover study of valproic acid and antiretroviral therapy to reduce the HIV reservoir.Generating protective immunity against genital herpesRapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.Inflammation and HIV Transmission in Sub-Saharan Africa.Inhibition of clinical pathogenic herpes simplex virus 1 strains with enzymatically created siRNA pools.Interventions for men and women with their first episode of genital herpes.A Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4+ and CD8+ T Cells.Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation.Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial.Attitudes and Willingness to Assume Risk of Experimental Therapy to Eradicate Genital Herpes Simplex Virus Infection.Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.Molecular evolution of herpes simplex virus 2 complete genomes: Comparison between primary and recurrent infections.Valacyclovir therapy does not reverse herpes-associated alterations in cervical immunology: a randomized, placebo-controlled crossover trial.Infection: high-dose antiviral therapy does not prevent short episodes of HSV-2 reactivation.Transcriptional Analysis of the Guinea Pig Mucosal Immune Response to Intravaginal Infection with Herpes Simplex Virus Type 2.
P2860
Q24194490-0408AF75-F189-444B-BD96-D0973E00AE09Q27324453-67635A87-F61F-4A45-961A-751F49FE33DFQ28236882-D13ACFC5-DDA3-493B-8A85-70F9A43227E6Q30402908-53302002-767F-4837-87D6-090444720CC7Q33870372-556AF297-0071-409E-BE63-9B4ACE0B93B1Q33931016-AD239B72-B528-486A-91C5-0B6C9CCC092BQ34345122-564A351A-0466-427E-B470-785CF2ACBC7DQ34540648-E5B750A4-0AA2-409D-BAD5-C7FB0FBC14C5Q34681733-C4353348-FA2A-4688-B84C-47E3D729E476Q35249684-8DEE3A64-A4E7-4902-8B30-0534DB45635EQ35544431-20A57E43-03FB-45F2-91A4-5E4E52B15FD0Q36173112-3E1B6D01-9049-4B2B-9148-B70BC0EBD21FQ36306926-EBAAF97F-1B08-48E6-AF76-833F89AA88B7Q36630996-0B17F063-9A8E-4AA7-A51D-AE1400DE42A9Q36730096-CFE3426F-8C0B-442B-BBF5-411415588E54Q36759693-F61CA4C0-8E6B-4072-B673-7D71007F2CE9Q36799919-620DE2D3-6284-494E-AEAB-57B304EB27EAQ36926843-285FAF84-8934-408D-8D88-D62C2DD6FAC5Q37003054-E0353D2F-B4DA-43AE-AC4F-01EB5DEB44C7Q37036440-483ED4F1-37F0-4860-84EF-C66E12304946Q37070372-256A6E8A-9083-4A30-8EB8-DCE40FAF83F2Q37212998-8A8190E5-47A8-4FCA-9F91-2290EDBC7FFFQ37273660-15D941C2-B97F-40AC-AC25-2FC98DEC28A7Q37283993-BFB48F49-A0A6-421E-B43C-FA1AAB4C7B8DQ37335794-28C793AF-EE94-465D-B387-0EEB0F1D410AQ37694574-7129BF3A-76F4-4FD8-B26D-4BB52CA6F61AQ38241377-269D0082-DD50-4006-A8A3-462B07D78FACQ38422546-20078DAD-265B-46DD-8D74-381E82A0BDEEQ38770194-F40F800F-8329-44B3-87BF-24E64BC70EA9Q38941189-1A77DA1E-0095-4705-9C55-242319A96F1FQ40067153-A40A0AF1-71C9-4ECC-88E7-BCB3513B8822Q40140509-2D63EB08-2554-4294-B9C5-937759B9B104Q40223016-29CB94E4-DD5F-400B-92CE-E90423550EEEQ40280300-F04092E2-F607-4152-8664-CBF05CFA99E1Q40579974-D19416A0-252F-4BA2-862A-C51A632AA24FQ41928445-85E1022F-0B81-4CB9-B081-4B2C5EB21D64Q41933426-10CCE9A1-FF39-4359-9F23-62CE5B4CFC6BQ42229344-C9F1F647-B421-4BAC-AA24-7F6415D9C45FQ44909687-0DF03904-C9DD-4B1F-8566-ABB7CE3C1AE9Q53697093-F5E438D3-0974-42BA-BF42-FB96C352CD37
P2860
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Standard-dose and high-dose da ...... open-label, cross-over trials.
@ast
Standard-dose and high-dose da ...... open-label, cross-over trials.
@en
type
label
Standard-dose and high-dose da ...... open-label, cross-over trials.
@ast
Standard-dose and high-dose da ...... open-label, cross-over trials.
@en
prefLabel
Standard-dose and high-dose da ...... open-label, cross-over trials.
@ast
Standard-dose and high-dose da ...... open-label, cross-over trials.
@en
P2093
P2860
P50
P1433
P1476
Standard-dose and high-dose da ...... open-label, cross-over trials.
@en
P2093
Amalia Magaret
Joshua T Schiffer
Misty Saracino
Stacy Selke
Steve Kuntz
P2860
P304
P356
10.1016/S0140-6736(11)61750-9
P407
P577
2012-01-04T00:00:00Z